ESR1 and breast carcinoma: Endocrine treatment is one of the most important approaches when it comes to ER+ breast cancers, and for metastatic disease it becomes the physician’s first choice, along with other targeted therapies (except in the case of a visceral crisis scenario, when chemotherapy should be the first choice).